ScholarIQanswers from OpenAlex
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
PaperCitations, authors & open-access status
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 480 citations, 2015 year and hybrid oa status.
480
Citations
2015
Year
hybrid
OA Status